Prognostic impact of unfavorable cytogenetic abnormalities in
multiple myeloma patients treated by bortezomib (velcade)

D 2007

Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade)

NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Romana ZAORALOVÁ, Hana FILKOVÁ, Petr KUGLÍK et. al.

Basic information

Original name

Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade)

Name in Czech

Prognostický vliv cytogenetických abnormalit u pacientů s mnohočetným myelomem léčených bortezomibem (Velcade)

Authors

NĚMEC, Pavel (203 Czech Republic), Henrieta GREŠLIKOVÁ (703 Slovakia), Romana ZAORALOVÁ (203 Czech Republic), Hana FILKOVÁ (203 Czech Republic), Petr KUGLÍK (203 Czech Republic), Alexandra OLTOVÁ (203 Czech Republic), Luděk POUR (203 Czech Republic), Zdeněk ADAM (203 Czech Republic), Andrea KŘIVANOVÁ (203 Czech Republic), Marta KREJČÍ (203 Czech Republic) and Roman HÁJEK (203 Czech Republic, guarantor)

Edition

Volume 92, no. 6 supplement. Pavia, Italy, Hematologica/The Hematology Journal, p. 165-165, 1 pp. 2007

Publisher

Ferrata-Storti Foundation

Other information

Language

English

Type of outcome

Stať ve sborníku

Field of Study

Genetics and molecular biology

Country of publisher

Italy

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 5.516

RIV identification code

RIV/00216224:14110/07:00022796

Organization unit

Faculty of Medicine

ISSN

UT WoS

000247425800331

Keywords in English

multiple myeloma; 1q21 amplifiaction; Velcade; fluorescence in situ hybridisation; DNA probe

Abstract

ORIG CZ

V originále

i) Introduction: The aim of this study is to investigate if Bortezomib (Velcade) is able to antagonize the impact of negative cytogenetic prognostic markers. We have focused on four chromosomal aberrations known as negative prognostic factors in multiple myeloma (MM) treated by conventional or myeloablastive treatment: deletion of RB gene (13q14), deletion of p53 (17p13), amplification of CKS1B gene (1q21) and translocation t(4;14). ii) Material and Methods: We have identified monotypic plasma cells and studied chromosomal aberrations by cytoplasmic light-chain fluorescence in situ hybridization (cIg-FISH) technique. Up-to-date group of 18 patients (pts.) has following characteristic: 67% of men, median age 62,5 years (44,4-77,9). 50% (9 pts.) were in stage IIIA, 28% (5 pts.) in IIA and 22% (4 pts.) in IA. 61% (11 pts.) were in first relapse, 22% (4 pts.) were in second relapse. The others 17% (3 pts.) were in third relapse. Treatment with Velcade based regimens was continued for up to 8 cycles in 66 % pts. (12/18). ii) Preliminary results: Cytogenetic findings: Deletion of RB gene was found in 8/16 (50%) pts., t(4;14) in 8/15 (53%) pts., deletion of p53 gene in 7/15 (47%) cases and amplification of CKS1B gene in 10/15 pts. (66%). Overall Response (OR) was 39% (0% CR, 11% VGPR, 28% PR). OR was not higher in pts. with cytogenetic findings for all aberration types except t(4;14): OR was 38% vs. 38% for pts. with vs. without deletion of RB gene; 63% vs. 14% for t(4;14) (p=0,240); 29% vs. 50% for deletion of p53 and 40% vs. 40% for amplification of CKS1B. Further, Velcade based therapy showed comparable TTP, DOR and OS in pts. with or without cytogenetic aberations including t(4;14). iv) Preliminary conclusions: We have found no significant difference when compared positivity vs. negativity of each cytogenetic aberration (including t(4;14)) for OR, TTP, DOR, PFS, and OS. This should have been caused by small size of our sample. It is possible that Velcade antagonizes the negative prognostic value of studied cytogenetic findings in MM. Supported by Myeloma Basic Research Centre Brno MU (LC 06027) and by grant from Ministry of Educations MSM0021622415.

In Czech

Práce pojednává o významu detekce chromozomálních aberací u pacientů s mnohočetným myelomem léčených bortezomibem (Velcade).

Links

LC06027, research and development project

Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)

Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group

MSM0021622415, plan (intention)

Name: Molekulární podstata buněčných a tkáňových regulací

Investor: Ministry of Education, Youth and Sports of the CR, Molecular basis of cell and tissue regulations

Citovat

NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Romana ZAORALOVÁ, Hana FILKOVÁ, Petr KUGLÍK, Alexandra OLTOVÁ, Luděk POUR, Zdeněk ADAM, Andrea KŘIVANOVÁ, Marta KREJČÍ and Roman HÁJEK. Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade). In Hematologica/The Hematology Journal. Volume 92, no. 6 supplement. Pavia, Italy: Ferrata-Storti Foundation, 2007, p. 165-165. ISSN 0390-6078.

@inproceedings{726964,
   author = {Němec, Pavel and Grešliková, Henrieta and Zaoralová, Romana and Filková, Hana and Kuglík, Petr and Oltová, Alexandra and Pour, Luděk and Adam, Zdeněk and Křivanová, Andrea and Krejčí, Marta and Hájek, Roman},
   address = {Pavia, Italy},
   booktitle = {Hematologica/The Hematology Journal},
   edition = {Volume 92, no. 6 supplement},
   keywords = {multiple myeloma; 1q21 amplifiaction; Velcade; fluorescence in situ hybridisation; DNA probe},
   language = {eng},
   location = {Pavia, Italy},
   pages = {165-165},
   publisher = {Ferrata-Storti Foundation},
   title = {Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade)},
   year = {2007}
}

TY  - JOUR
ID  - 726964
AU  - Němec, Pavel - Grešliková, Henrieta - Zaoralová, Romana - Filková, Hana - Kuglík, Petr - Oltová, Alexandra - Pour, Luděk - Adam, Zdeněk - Křivanová, Andrea - Krejčí, Marta - Hájek, Roman
PY  - 2007
TI  - Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade)
PB  - Ferrata-Storti Foundation
CY  - Pavia, Italy
KW  - multiple myeloma
KW  - 1q21 amplifiaction
KW  - Velcade
KW  - fluorescence in situ hybridisation
KW  - DNA probe
N2  - i) Introduction: The aim of this study is to investigate if Bortezomib (Velcade) is able to antagonize the impact of negative cytogenetic prognostic markers. We have focused on four chromosomal aberrations known as negative prognostic factors in multiple myeloma (MM) treated by conventional or myeloablastive treatment: deletion of RB gene (13q14), deletion of p53 (17p13), amplification of CKS1B gene (1q21) and translocation t(4;14). ii) Material and Methods: We have identified monotypic plasma cells and studied chromosomal aberrations by cytoplasmic light-chain fluorescence in situ hybridization (cIg-FISH) technique. Up-to-date group of 18 patients (pts.) has following characteristic: 67% of men, median age 62,5 years (44,4-77,9). 50% (9 pts.) were in stage IIIA, 28% (5 pts.) in IIA and 22% (4 pts.) in IA. 61% (11 pts.) were in first relapse, 22% (4 pts.) were in second relapse. The others 17% (3 pts.) were in third relapse. Treatment with Velcade based regimens was continued for up to 8 cycles in 66 % pts. (12/18). ii) Preliminary results: Cytogenetic findings: Deletion of RB gene was found in 8/16 (50%) pts., t(4;14) in 8/15 (53%) pts., deletion of p53 gene in 7/15 (47%) cases and amplification of CKS1B gene in 10/15 pts. (66%). Overall Response (OR) was 39% (0% CR, 11% VGPR, 28% PR). OR was not higher in pts. with cytogenetic findings for all aberration types except t(4;14): OR was 38% vs. 38% for pts. with vs. without deletion of RB gene; 63% vs. 14% for t(4;14) (p=0,240); 29% vs. 50% for deletion of p53 and 40% vs. 40% for amplification of CKS1B. Further, Velcade based therapy showed comparable TTP, DOR and OS in pts. with or without cytogenetic aberations including t(4;14). iv) Preliminary conclusions: We have found no significant difference when compared positivity vs. negativity of each cytogenetic aberration (including t(4;14)) for OR, TTP, DOR, PFS, and OS. This should have been caused by small size of our sample. It is possible that Velcade antagonizes the negative prognostic value of studied cytogenetic findings in MM. Supported by Myeloma Basic Research Centre Brno MU (LC 06027) and by grant from Ministry of Educations MSM0021622415.
ER  -

NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Romana ZAORALOVÁ, Hana FILKOVÁ, Petr KUGLÍK, Alexandra OLTOVÁ, Luděk POUR, Zdeněk ADAM, Andrea KŘIVANOVÁ, Marta KREJČÍ and Roman HÁJEK. Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade). In \textit{Hematologica/The Hematology Journal}. Volume 92, no. 6 supplement. Pavia, Italy: Ferrata-Storti Foundation, 2007, p.~165-165. ISSN~0390-6078.

Detailed Information on Publication Record